2'-azido-2'-deoxyuridine

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 2'-azido-2'-deoxyuridine
• 英文别名: 1-[(2R,4S,5R)-3-azido-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
• 化学式: C₉H₁₁N₅O₅
• 分子量: 269.217
• InChiKey: MRUKYOQQKHNMFI-RNMRRNDGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2'-azido-2'-deoxyuridine 在 苯甲醛 作用下， 以 水 、 一水合肼 为溶剂， 生成 2-azido-2-deoxyribose
  参考文献：
  名称：

  US4145531

  摘要：

  公开号：

文献信息

• SYNTHESIS AND STRUCTURE OF HIGH POTENCY RNA THERAPEUTICS
  申请人：Arcturus Therapeutics, Inc.

  公开号：US20190002906A1

  公开（公告）日：2019-01-03

  This invention provides expressible polynucleotides, which can express a target protein or polypeptide. Synthetic mRNA constructs for producing a protein or polypeptide can contain one or more 5′ UTRs, where a 5′ UTR may be expressed by a gene of a plant. In some embodiments, a 5′ UTR may be expressed by a gene of a member of Arabidopsis genus. The synthetic mRNA constructs can be used as pharmaceutical agents for expressing a target protein or polypeptide in vivo.

  这项发明提供了可表达的多核苷酸，可以表达目标蛋白质或多肽。用于产生蛋白质或多肽的合成mRNA构建物可以包含一个或多个5' UTR，其中5' UTR可以由植物的基因表达。在某些实施例中，5' UTR可以由拟南芥属植物的基因表达。这些合成mRNA构建物可以用作体内表达目标蛋白质或多肽的药用剂。
• [EN] COMPOSITION AND METHODS FOR TREATMENT OF PRIMARY CILIARY DYSKINESIA<br/>[FR] COMPOSITION ET MÉTHODES DE TRAITEMENT D'UNE DYSKINÉSIE CILIAIRE PRIMITIVE
  申请人：TRANSLATE BIO INC

  公开号：WO2021226463A1

  公开（公告）日：2021-11-11

  The present invention provides, among other things, methods and compositions for treating primary ciliary dyskinesia (PCD) based on mRNA therapy. The compositions used in treatment of PCD comprise an mRNA comprising a dynein axonemal intermediate chain 1 (DNAI1) coding sequence and are administered at an effective dose and an administration interval such that at least one symptom or feature of PCD is reduced in intensity, severity, or frequency or has a delayed onset. mRNAs with optimized DNAI1 coding sequences are provided that can be administered without the need for modifying the nucleotides of the mRNA to achieve sustained in vivo function.

  本发明提供了治疗原发性纤毛运动障碍（PCD）的方法和组合物，基于mRNA疗法。用于治疗PCD的组合物包括一个包含动力蛋白纤毛中间链1（DNAI1）编码序列的mRNA，以有效剂量和给药间隔进行给药，以使PCD的至少一个症状或特征在强度、严重程度、频率上减轻，或延迟发作。提供了具有优化DNAI1编码序列的mRNA，可以在不需要修改mRNA核苷酸的情况下进行给药，以实现体内持续功能。
• Inhibitors of RecA activities for control of antibiotic-resistant bacterial pathogens
  申请人：Singleton Fain Scott

  公开号：US20060199768A1

  公开（公告）日：2006-09-07

  Compounds for modulating RecA protein activity are provided. In some embodiments, the compounds modulate RecA activity by interfering with assembly of monomeric RecA protein subunits into a nucleoprotein filament. In some embodiments, the compounds modulate RecA activity by interfering with adenosine triphosphate hydrolysis by the RecA protein. Methods of screening for and methods of using the compounds are also provided.

  提供了用于调节RecA蛋白活性的化合物。在某些实施例中，这些化合物通过干扰单体RecA蛋白亚基的组装成为核蛋白丝来调节RecA活性。在某些实施例中，这些化合物通过干扰RecA蛋白的三磷酸腺苷水解来调节RecA活性。还提供了筛选这些化合物的方法和使用这些化合物的方法。
• Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs
  申请人：Drug Innovation & Design, Inc.

  公开号：US20030138432A1

  公开（公告）日：2003-07-24

  The present invention relates to the compositions, methods, and applications of a novel approach to selective cellular targeting. The purpose of this invention is to enable the selective delivery and/or selective activation of effector molecules to target cells for diagnostic or therapeutic purposes. The present invention relates to multi-functional prodrugs or targeting vehicles wherein each functionality is capable of enhancing targeting selectivity, affinity, intracellular transport, activation or detoxification. The present invention also relates to ultra-low dose, multiple target, multiple drug chemotherapy and targeted immunotherapy for cancer treatment.

  本发明涉及一种新的选择性细胞靶向的组合物、方法和应用。本发明的目的是为了实现对目标细胞的选择性输送和/或选择性激活效应分子，以进行诊断或治疗。本发明涉及多功能前药或靶向载体，其中每个功能都能增强靶向选择性、亲和力、细胞内转运、激活或解毒。本发明还涉及超低剂量、多靶点、多药物化疗和靶向免疫疗法，用于癌症治疗。
• Solid phase sequencing of double-stranded nucleic acids
  申请人：——

  公开号：US20030096258A1

  公开（公告）日：2003-05-22

  Methods for detecting and sequencing of target double-stranded nucleic acid molecules, nucleic acid probes and arrays of probes useful in these methods, and kits and systems that contain these probes aer provided. The methods involve hybridizing the nucleic acids or nucleic acids which represent complementary or homologous sequences of the target to an array of nucleic acid probes. These probes include a single-stranded portion, an optional double-stranded portion and a variable sequence within the single-stranded portion. The molecular weights of the hybridized nucleic acids of the set can be determined by mass spectroscopy, and the sequence of the target determined from the molecular weights of the fragments.

  提供了用于检测和测序目标双链核酸分子的方法，用于这些方法的核酸探针和探针阵列，以及包含这些探针的试剂盒和系统。这些方法涉及将与目标互补或同源序列相对应的核酸或核酸的杂交到核酸探针阵列上。这些探针包括单链部分、可选的双链部分和单链部分内的可变序列。可以通过质谱法确定一组杂交核酸的分子量，并从碎片的分子量确定目标的序列。